Abdominal Aortic Aneurysm Without Rupture
Conditions
Keywords
Abdominal Aortic Aneurysm, Magnetic Resonance Imaging, 4D flow MRI, DCE MRI
Brief summary
An abdominal aortic aneurysm (AAA) is a pathological dilatation of the aorta in the belly which can rupture leading to bleeding within the belly. To prevent rupture elective surgery can be performed. Endovascular repair (EVAR) is a surgical intervention whereby a stent is inserted into the AAA to prevent it from further growth and rupture. Standard AAA management has several drawbacks. To start: maximum AAA diameter is used to determine upon timing of elective repair but is imprecise in predicting the risk of rupture resulting in an unmet clinical need. Secondly, EVAR outcome and complication occurrence remain unpredictable due to poor prediction ability of computed tomography (CT) and ultrasound (US) utilised in the follow-up protocol. Lastly, patients and physicians are being repeatedly exposed to cumulative radiation toxicity. All these drawbacks could be solved by trading the standard imaging modalities by magnetic resonance imaging (MRI). Within the MARVY, advanced MRI techniques are used to find out if standard imaging techniques could be replaced by MRI in three phases of the AAA management (surveillance, surgery planning and post-operative follow-up). The two most important MRI techniques that will be used are 4D flow MRI and dynamic contrast enhanced (DCE) MRI which give respectively information about the blood flow within the AAA and perfusion of the aortic wall.
Interventions
Philips Ingenia 3.0T MR system with in-house developed PROUD software
Sponsors
Study design
Eligibility
Inclusion criteria
* diagnosed with AAA * provision of written informed consent Inclusion Criteria for surveillance part: * maximum AAA diameter between 3-5 cm * not scheduled for aneurysm repair at the time of inclusion Inclusion Criteria for planning part: * planned for elective EVAR Inclusion Criteria for follow-up part: * ten complication free years after EVAR or sac regression after EVAR; or * type I endoleak after EVAR; or * type II endoleak after EVAR;
Exclusion criteria
* Supra- or pararenal AAA * Inflammatory, infectious or mycotic AAA * Vasculitis and connective tissue disease * Patients that underwent open surgical repair for their AAA * Patients with ruptured AAAs * Patients that previously presented with allergic reactions to intravenous contrast agents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Surveillance: correlation between growth rate and MRI derived parameters | 1 year | The main study parameter for phase B1 (surveillance) is the correlation between growth rate of the AAA (determinant for the standard of care) and measured MRI parameters acquired with 4D flow MRI and DCE-MRI. |
| EVAR planning: correlation between morphological parameters measured based on MRA and CTA | half year | The main study parameter for phase B2 (EVAR planning) is the difference between anatomical measurements (lengths and diameters) based on both CTA and MRA. Several quantitative anatomical measurements will be utilised to assess the feasibility of MRA for planning of EVARs. |
| EVAR follow up: difference in MRI parameters between patients with endoleaks and without | 1 year | The main study parameter for phase B3 (EVAR follow-up) is the difference in MRI parameters measured post-operatively in patients with and without EVAR related complications. |
Countries
Netherlands